Browsing Modes for Business Users

Mumps Virus

Product Code Applications Pack Size List Price Your Price Qty
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
E 1 ml loader
List Price Your Price

Native mumps virus preparation Native mumps virus contains a high concentration of virus and viral components. The preparation also contains some cellular material suspended in tissue culture medium (1969B).

Mumps virus is a member of the Paramyxoviridae family and is the causative agent of mumps. Mumps is most typically characterised by painful swelling of the salivary glands and fever. In some adult men, the virus might also infect the testicles, rarely causing sterility. The virus is spread by airborne droplets from the nose or throat and can have an incubation period of up to three weeks. Infected individuals are contagious from approximately 6 days before until about 9 days after the onset of symptoms. The disease is self-limiting and treatment involves controlling specific symptoms. An effective vaccine exists and may be given separately or as part of the MMR vaccine.

Target Species
Product Form
Inactivated Mumps virus - liquid
Mumps virus, Enders strain, cultured in BSC-1 cells. Optimally infected cells are harvested, disrupted by sonication in culture medium and subjected to low speed centrifugation. The supernatant from the infected culture is concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material.
Buffer Solution
Culture medium 1969B
Preservative Stabilisers
None present
Antigenic activity is 51.1% of internal reference batch
Approx. Protein Concentrations
Current, batch-specific concentration 1.0 mg/ml
For research purposes only
12 months from date of despatch

Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Instructions For Use
PIP014 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.

References for Mumps Virus

  1. Bhoj, V.G. et al. (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
    Blood. 128 (3): 360-70.
  2. Riggenbach, M.M. et al. (2021) Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents.
    Clin Immunol. 234: 108912.
  3. Böröcz, K. et al. (2022) Dynamic Features of Herd Immunity: Similarities in Age-Specific Anti-Measles Seroprevalence Data between Two Countries of Different Epidemiological History.
    J Clin Med. 11(4):1145.
  4. Wang, L. et al. (2023) Associations of adaptive immune cell subsets with measles, mumps, and Rubella−Specific immune response outcomes
    Heliyon. 9 (12): e22998.
  5. Ovsyannikova, I.G. et al. (2023) Genome-wide determinants of cellular immune responses to mumps vaccine.
    Vaccine. 41 (44): 6579-88.
  6. Szinger, D. et al. (2023) Following Natural Autoantibodies: Further Immunoserological Evidence Regarding Their Silent Plasticity and Engagement in Immune Activation.
    Int J Mol Sci. 24 (19)Oct 06 [Epub ahead of print].
  7. Szinger, D. et al. (2024) Raising Epidemiological Awareness: Assessment of Measles/MMR Susceptibility in Highly Vaccinated Clusters within the Hungarian and Croatian Population—A Sero-Surveillance Analysis
    Vaccines. 12 (5): 486.

GO Terms
GO:0003723 RNA binding
GO:0030529 ribonucleoprotein complex
GO:0005198 structural molecule activity
GO:0019013 viral nucleocapsid
GO:0030430 host cell cytoplasm


149234 151308 151309 155669 155926 158888

If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.

Request a different product with this specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Viral Products
Please note